Danske Bank A S Sells 22,251 Shares of STERIS plc $STE

Key Points

• Danske Bank A/S trimmed its stake in STERIS by 28.7%, selling 22,251 shares in Q4 and now holds 55,410 shares valued at about $14.05 million (0.06% of the company).
• Company results and guidance: STERIS reported Q EPS of $2.53 (in line with estimates) with revenue up 9.2% year-over-year and set FY2026 EPS guidance of $10.15–$10.30 (analysts expect ~10.22); the stock trades near $215 with a ~$21.1B market cap and ~30x P/E.
• Insider and market sentiment: Director Cynthia Feldmann sold 3,098 shares (reducing her stake by ~81%), insiders own 1.07%, institutional ownership is ~94.7%, and analysts' consensus is a "Moderate Buy" with a $275.20 target.

Danske Bank A S trimmed its holdings in STERIS plc (NYSE:STE - Free Report) by 28.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,410 shares of the medical equipment provider's stock after selling 22,251 shares during the quarter. Danske Bank A S owned 0.06% of STERIS worth $14,048,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Steigerwald Gordon & Koch Inc. bought a new position in STERIS in the third quarter worth $25,000. Board of the Pension Protection Fund bought a new position in STERIS in the fourth quarter worth $25,000. Activest Wealth Management lifted its position in STERIS by 423.8% in the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 89 shares during the period. Harbor Investment Advisory LLC lifted its position in STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 60 shares during the period. Finally, Cloud Capital Management LLC bought a new position in STERIS in the third quarter worth $29,000. 94.69% of the stock is owned by institutional investors.

STERIS Stock Up 0.2%

Shares of NYSE STE opened at $214.78 on Monday. The stock has a market cap of $21.06 billion, a PE ratio of 29.96 and a beta of 0.95. The business has a fifty day moving average of $226.36 and a two-hundred day moving average of $244.80. STERIS plc has a 52-week low of $209.98 and a 52-week high of $269.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The business's revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, equities research analysts expect that STERIS plc will post 10.22 earnings per share for the current fiscal year.

Insider Activity

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the transaction, the director directly owned 705 shares of the company's stock, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.07% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on STE shares. Wall Street Zen cut STERIS from a "strong-buy" rating to a "buy" rating in a research report on Sunday, April 26th. Weiss Ratings cut STERIS from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, April 16th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, STERIS has an average rating of "Moderate Buy" and a consensus target price of $275.20.

STERIS Company Profile

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.